17:51 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Obesity Cell culture and mouse studies suggest inhibiting MMP2 in the hypothalamus could help treat obesity. In a high-fat diet-induced mouse model of obesity, systemic MMP2 knockout decreased food intake and weight gain compared...
23:03 , Aug 22, 2018 |  BC Extra  |  Preclinical News

Inhibiting MMP2 reverses leptin resistance associated with obesity

University of California San Diego researchers and colleagues showed that inhibiting cleavage of leptin receptor (LEPR; CD295) by matrix metalloproteinase 2 (MMP2) could help prevent leptin resistance and treat obesity. Obesity is associated with high...
16:02 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Rheumatoid arthritis (RA) Patient sample and mouse studies suggest a hydrogel-based formulation of the GCCR agonist triamcinolone acetonide could help treat RA and other forms of inflammatory arthritis. The hydrogel contains injectable triglycerol monostearate...
19:10 , Aug 22, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Nanoparticles that promote tumor platelet phagocytosis could be used to delivery cancer therapies. The nanoparticles consist of a polyethylenimine (PEI)-poly(glycolic acid) core that contains drug cargo and a mAb targeting glycoprotein Ib (platelet)...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

AQU-005: Phase I started

NeuroMax began an open-label, Russian Phase I trial to evaluate AQU-005 in 24 healthy volunteers. NeuroMax plans to begin proof-of-concept (POC) trials of the product in patients with neuropathic pain in 4Q16. NeuroMax has worldwide...
07:00 , Sep 24, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Matrix metalloproteinase 2 (MMP2); MMP9; MMP14

Cancer INDICATION: Cancer Cell and mouse studies identified an inhibitor of MMP2 , MMP9 , and MMP14 that could help treat cancer. Chemical synthesis and testing in an MMP binding assay of sulfonamide hydroxamate analogs...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug delivery

This week in techniques Approach Summary Licensing status Publication and contact information Drug delivery Matrix metalloproteinase 2 (MMP2)-activated, chemotherapeutic nanocarriers for targeted drug delivery MMP2-activated nanocarriers could provide a drug delivery vehicle for cancer chemotherapies....
07:00 , Oct 3, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Imaging

Approach Summary Licensing status Publication and contact information Imaging Secondary Cherenkov-induced fluorescence imaging (SCIFI) to detect markers of disease activity Mouse studies suggest SCIFI could help detect and monitor markers of disease activity. SCIFI relies...
07:00 , Jul 15, 2013 |  BioCentury  |  Regulation

Coding for utility

New, tougher requirements for obtaining Medicare coverage are increasing the cost and time needed to get laboratory-developed molecular diagnostics onto the market and decreasing the certainty that they will be covered. Empowered by a new...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Company News

Predictive Biosciences diagnostic news

Predictive Biosciences is ceasing operations and laying off all 91 employees after CMS contractor CGS Administrators LLC decided to deny coverage for the company's bladder cancer diagnostics. CEO Pierre Cassigneul told BioCentury that the company...